Advanced Linker Technology for Antibody-Drug Conjugates

Antibody-drug conjugates (ADCs) are a promising class of biopharmaceuticals, that combine the specificity of therapeutic antibodies with the pharmacological potency of chemical, cytotoxic drugs. Ever since the first ADCs came to the market, ADC technologies have emerged, such as antibody engineering. However, there remain gaps in the development of linker optimisation and novel conjugation strategies. This project will focus on new linker technologies that will help to promote conjugate homogeneity and overall ADC stability.